What is CohBar?
CohBar is pioneering mitochondria-based therapeutics, an emerging drug class aimed at treating chronic and age-related conditions. The company's scientific foundation lies in the discovery of naturally occurring peptide sequences within the mitochondrial genome. These peptides have demonstrated potential in regulating key physiological processes, offering a new avenue for therapeutic intervention. CohBar's lead compound, CB4211, has completed Phase 1a/1b clinical trials for nonalcoholic steatohepatitis (NASH) and obesity. Additionally, the company is advancing four preclinical programs, including CB5138-3 for idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases, which is currently in IND-enabling studies. Other preclinical efforts target acute respiratory distress syndrome (ARDS), cancer immunotherapy, and orphan diseases.
How much funding has CohBar raised?
CohBar has raised a total of $11.3M across 1 funding round:
Stock Offering
$11.3M
Stock Issuance/Offering (2015): $11.3M, investors not publicly disclosed
What's next for CohBar?
With the recent infusion of capital, CohBar is strategically positioned to advance its pipeline of mitochondria-based therapeutics. The company's focus will likely be on progressing its lead compound through further clinical development and accelerating its preclinical programs towards human trials. This enterprise-level funding provides the necessary resources to navigate the complex drug development process, conduct rigorous clinical studies, and potentially expand its therapeutic reach into new disease areas. The strategic nature of the investment suggests potential collaborations or synergistic opportunities that could enhance CohBar's market position and accelerate the commercialization of its innovative treatments.
See full CohBar company page
